The Intersectional Viborg Screening Program: Cost-(Effectiveness) of Screening for Diabetes and Cardiovascular Diseases
VISP
Intersectional Screening Program for Diabetes and Cardiovascular Diseases Among 67-years Old Citizens of the Municipal of Viborg
1 other identifier
observational
4,500
1 country
1
Brief Summary
This is an intersectional and interdisciplinary screening program in Viborg Municipality, including 67 years old citizens. This observational study will estimate the cost-effectiveness of a combined screening program for the following conditions: Abdominal aortic aneurysm, peripheral arterial disease, carotid plaque, hypertension, arrhythmia, and type-2-diabetes. Furthermore, the incidence of the outlined conditions will be described and so will the result of the intervention initiated (secondary medical prophylaxis, smoking cessation, introduction to nutritionally deficient diet etc.)
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2014
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2014
CompletedFirst Submitted
Initial submission to the registry
March 15, 2017
CompletedFirst Posted
Study publicly available on registry
January 10, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2029
February 1, 2024
January 1, 2024
13 years
March 15, 2017
January 31, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Baseline prevalence of peripheral arterial disease (PAD) in men and women aged 67 years from a population screening study on the Municipal of Viborg.
Ankel Brachial Index
Inclusion will take place from sep. 2014 to sep. 2020
Baseline prevalence of abdominal aortic aneurysm (AAA)
Ultra sound examination (AP diameter (mm))
Inclusion will take place from sep. 2014 to sep. 2020
Baseline prevalence of diabetes
Bedside HbA1c
Inclusion will take place from sep. 2014 to sep. 2020
Baseline prevalence of hypertension
BP(mmhg)
Inclusion will take place from sep. 2014 to sep. 2020
Baseline prevalence of cardiac arrythmia
ECG
Inclusion will take place from sep. 2014 to sep. 2020
Baseline prevalence of carotic plaques
Ultra sound examination of A. carotis (IMT in mm)
Inclusion will take place from sep. 2014 to sep. 2020
Secondary Outcomes (1)
The cost(-effectiveness) of the screening program
5 years after ending inclusion
Eligibility Criteria
All Viborg municipality citizen are invited to the combined screening program around there 67th birthday. Participants with positive screening results are offered following up consultations and prophylactic interventions are initiated (secondary medical prophylaxis, smoking cessation, introduction to nutritionally deficient diet etc.) 67 years-old citizens from the surrounding municipalities without the offer of the combined screening are used as a control group (1 case: 5 controls).
You may qualify if:
- All Viborg municipality citizen are invited to the combined screening program around there 67th birthday.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Central Jutland Regional Hospitallead
- Odense University Hospitalcollaborator
Study Sites (1)
Cardiovascular research Center (KVC), Viborg Hospital
Viborg, 8800, Denmark
Related Publications (5)
Van Der Giessen D, Hogh A, Svenstrup D, Lindholt JS, Dahl M. Clinical relevance of screening for ECG abnormalities in 67-year-old Danes: a population-based cohort study from the Viborg Screening Programme (VISP). BMJ Open. 2025 Dec 23;15(12):e104169. doi: 10.1136/bmjopen-2025-104169.
PMID: 41436274DERIVEDGras Hojgaard H, Hogh AL, Lindholt JS, Frederiksen K, Dahl M. Effect of nurse-led telephone follow-up to optimize adherence to preventive medication after screen-detected cardiovascular disease: a randomized controlled trial. Eur J Cardiovasc Nurs. 2025 Jul 21;24(5):748-759. doi: 10.1093/eurjcn/zvaf047.
PMID: 40130283DERIVEDAndersen JW, Hogh A, Lindholt JS, Sogaard R, Stovring H, Yderstraede KB, Sandbaek A, Dahl M. Impact of Population-Based Screening for Diabetes and Prediabetes Among 67-Year-Olds Using Point-of-Care HbA1c on Healthcare Ultilisation, Results from the VISP Cohort. Clin Epidemiol. 2025 Feb 5;17:75-85. doi: 10.2147/CLEP.S487825. eCollection 2025.
PMID: 39926308DERIVEDDahl M, Andersen JW, Lindholt J, Krarup NT, Borregaard B, Uberg N, Hogh A. Prevalence of interarm blood pressure difference is notably higher in women; the Viborg population-based screening program (VISP). BMC Public Health. 2024 Jul 12;24(1):1868. doi: 10.1186/s12889-024-19388-8.
PMID: 38997668DERIVEDHogh A, Lindholt JS, Sogaard R, Refsgaard J, Svenstrup D, Moeslund NJ, Bredsgaard M, Dahl M. Protocol for a cohort study to evaluate the effectiveness and cost-effectiveness of general population screening for cardiovascular disease: the Viborg Screening Programme (VISP). BMJ Open. 2023 Feb 28;13(2):e063335. doi: 10.1136/bmjopen-2022-063335.
PMID: 36854592DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
Annette Høgh, MD, PhD
Steering Committee
- STUDY DIRECTOR
Marie Dahl, MSc(nurse)
Steering Committee
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD, Associated professor
Study Record Dates
First Submitted
March 15, 2017
First Posted
January 10, 2018
Study Start
August 1, 2014
Primary Completion (Estimated)
August 1, 2027
Study Completion (Estimated)
August 1, 2029
Last Updated
February 1, 2024
Record last verified: 2024-01